Development of an Inactivated Vaccine against SARS CoV-2
The rapid spread of SARS-CoV-2 with its mutating strains has posed a global threat to safety during this COVID-19 pandemic. Thus far, there are 123 candidate vaccines in human clinical trials and more than 190 candidates in preclinical development worldwide as per the WHO on 1 October 2021. The vari...
Guardado en:
Autores principales: | Shaikh Terkis Islam Pavel, Hazel Yetiskin, Muhammet Ali Uygut, Ahmet Furkan Aslan, Günsu Aydın, Öznur İnan, Büşra Kaplan, Aykut Ozdarendeli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4fffaa2b7df34c4dbd3ef7efa5cc7fbf |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
por: Felipe Melo-González, et al.
Publicado: (2021) -
Vacuna anti hepatitis A
por: COFRÉ G.,JOSÉ, et al.
Publicado: (2003) -
Predictive and Experimental Immunogenicity of <i>Burkholderia</i> Collagen-like Protein 8-Derived Antigens
por: Megan E. Grund, et al.
Publicado: (2021) -
Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: a non-inferiority, randomised controlled trial
por: Yan Li, et al.
Publicado: (2021) -
Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization
por: Jin Wang, et al.
Publicado: (2021)